digestVidSign in
summary

UCLA Health - Can Blocking CCR5 Improve Brain Injury and Dementia Recovery?

Thumbnail of the video “UCLA Health - Can Blocking CCR5 Improve Brain Injury and Dementia Recovery?”
Community upload. AI output has not been independently verified.
Author: UCLA Health
Categories: Health
Tags: health
Views: 2 · Last viewed: 2026-10-16 15:01 UTC

Short Summary

Main recommendation: Researchers at UCLA Health are studying CCR5 blockade, using the existing FDA-approved drug maraviroc, as a way to improve recovery after stroke and traumatic brain injury, with timing set after an early vulnerable window. In mouse models, blocking CCR5 after the first few days improved motor recovery and, in traumatic brain injury models, cognitive recovery, and a clinical trial is ongoing in Canada. The work is still preclinical and early clinical, and the speaker says key questions about dosing duration remain open.

Key Points

  • CCR5 is turned on strongly after stroke and helps limit early injury by reducing neuron excitability, but this same system can persist and limit recovery later.
  • In stroke mouse models, blocking CCR5 after the early injury window produced substantially better recovery, with improvements in forelimb motor control and walking.
  • Recovery changes observed included neuron connection growth on both sides of the brain, axon sprouting, and sustained dendritic spines rather than their loss.
  • The speaker's collaborator studied CCR5 blockade in a traumatic brain injury model and found it improved cognitive recovery at a clinically meaningful amount similar to the motor gains seen in stroke.
  • The speaker cites a study of patients with a loss-of-function CCR5 mutation who recovered better after brain injury, and mentions an ongoing clinical trial in Canada.
  • The speaker's collaborator (Elisino Silva) published findings that in aged mice, CCR5 blockade restored memory performance to levels resembling younger mice, and this line of research is being pursued further.

Details Worth Noting

  • Concrete instructions: Do not give a CCR5 blocker during roughly the first three to five days after stroke, because it may worsen injury during that unstable window; start treatment after that period to promote recovery.
  • Concrete instructions: The drug named in the transcript for CCR5 blockade is maraviroc, an FDA-approved drug used by about 15 percent of HIV patients, which the speaker says allowed the research to move into clinical trials quickly.
  • Concrete instructions: In mice, dosing was daily for about a month, and up to three months in some animals; the speaker says human dosing duration is not yet known and needs testing. The ongoing Canadian trial gives the drug twice a day, and the speaker recalled a duration of around 60 days but asked for confirmation.
  • The speaker notes the hypothesis that CCR5 blockade tightens connections between the two motor planning areas, so the other hemisphere can compensate if one side is damaged; this is described as a hypothesis, not a proven mechanism.
  • The anti-inflammatory role of CCR5 in microglia was not considered a major factor in the recovery effect, since receptor expression there drops about 12 hours after injury, while neuronal CCR5 remains elevated for weeks.
  • The speaker says the minimal clinically important difference for memory in traumatic brain injury is less established than for motor function.

Bottom Line

Blocking CCR5 after the early post-injury window shows promise for recovery in animal studies, and the existing drug maraviroc offers a faster path into human testing, but dosing, timing, and clinical benefit in people remain to be confirmed.